Vaccine-induced human antibodies specific for the third variable region of HIV-1 gp120 impose immune pressure on infecting viruses

• Main Authors: Susan Zolla-Pazner, Paul T. Edlefsen, Morgane Rolland, Xiang Peng Kong, Allan deCamp, Raphael Gottardo, Constance Williams, Sodsai Tovanabutra, Sandra Sharpe-Cohen, James I. Mullins, Mark S. deSouza, Nicos Karasavvas, Sorachai Nitayaphan, Supachai Rerks-Ngarm, Punnee Pitisuttihumi, Jaranit Kaewkungwal, Robert J. O'Connell, Merlin L. Robb, Nelson L. Michael, Jerome H. Kim, Peter Gilbert
• Other Authors: New York Veterans Affairs Harbor Healthcare System
• Format: Article
• Published: 2018
• Subjects: Biochemistry, Genetics and Molecular Biology
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/33496
• Institution: Mahidol University

© 2014 The Authors. To evaluate the role of V3-specific IgG+antibodies (Abs) in the RV144 clinical HIV vaccine trial, which reducedHIV-1 infection by 31.2%, the anti-V3 Ab response was assessed. Vaccinees' V3 Abs were highly cross-reactivewith cyclic V3 peptides (cV3s) from diverse virus subtyp...